title: [Research progress of bevacizumab in the treatment of refractory epistaxis caused by hereditary hemorrhagic telangiectasia].
abstract: Hereditary hemorrhagic telangiectasia(HHT) is an autosomal disorder characterized by hemorrhage and abnormal blood vessels. Spontaneous recurrent epistaxis is the most common manifestation, and the severity of nosebleed develops with age increasing. However, there is no effect treatment for HHT-related epistaxis until now. Recently, bevacizumab shows significant effect in the treatment of HHT and the related literatures are increasing gradually. This article will review the studies focused on bevacizumab in the treatment of HHT-related refractory nasal bleeding.
authors.affiliation: Department of Otorhinolaryngology Head and Neck Surgery, Chinese People's Liberation Army General Hospital, Beijing 100853, China.
authors.forename: C
authors.initials: C
authors.lastname: Xu
authors.affiliation: Department of Otorhinolaryngology Head and Neck Surgery, Chinese People's Liberation Army General Hospital, Beijing 100853, China; Department of Otorhinolaryngology Head and Neck Surgery, Hainan Branch of Chinese People's Liberation Army General Hospital, Sanya 572000, China.
authors.forename: H T
authors.initials: HT
authors.lastname: Wang
mesh_terms: D000068258:Bevacizumab / Q000627:therapeutic use*; D004844:Epistaxis / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D013683:Telangiectasia, Hereditary Hemorrhagic / Q000150:complications*
chemical_list: D000068258:Bevacizumab